OBJECTIVES: To investigate whether aerosolized prostacyclin improves oxygenation in children with acute lung injury. DESIGN: Double-blind, randomized, and placebo-controlled trial. SETTING:Pediatric intensive care unit at a university hospital. PATIENTS: Fourteen children with acute lung injury defined by the criteria of an American-European Consensus Conference. INTERVENTIONS:Aerosolized prostacyclin (epoprostenol sodium) by stepwise increments of different doses (10, 20, 30, 40, and 50 ng x kg x min) vs. aerosolized normal saline (placebo). MEASUREMENTS AND MAIN RESULTS: Before the start of the study, and before and after each dose of prostacyclin/placebo, the following variables were measured: arterial blood gases, heart rate, mean arterial blood pressure, and ventilator settings required. Changes in oxygenation were measured by calculation of the oxygenation index (mean airway pressure x 100 x Pao2/Fio2). After treatment with aerosolized prostacyclin, there was a significant 26% (interquartile range, 3%, 35%) improvement in oxygenation index at 30 ng x kg x min compared with placebo (p =.001). The response to prostacyclin was not the same in all children. We saw an improvement of > or = 20% in eight of 14 children (i.e., responders), and the number needed to treat was 1.8 (95% confidence interval, 1.2-3.2). No adverse effects were observed. CONCLUSIONS:Aerosolized prostacyclin improves oxygenation in children with acute lung injury. Future trials should investigate whether this treatment will positively affect outcome.
RCT Entities:
OBJECTIVES: To investigate whether aerosolized prostacyclin improves oxygenation in children with acute lung injury. DESIGN: Double-blind, randomized, and placebo-controlled trial. SETTING: Pediatric intensive care unit at a university hospital. PATIENTS: Fourteen children with acute lung injury defined by the criteria of an American-European Consensus Conference. INTERVENTIONS: Aerosolized prostacyclin (epoprostenol sodium) by stepwise increments of different doses (10, 20, 30, 40, and 50 ng x kg x min) vs. aerosolized normal saline (placebo). MEASUREMENTS AND MAIN RESULTS: Before the start of the study, and before and after each dose of prostacyclin/placebo, the following variables were measured: arterial blood gases, heart rate, mean arterial blood pressure, and ventilator settings required. Changes in oxygenation were measured by calculation of the oxygenation index (mean airway pressure x 100 x Pao2/Fio2). After treatment with aerosolized prostacyclin, there was a significant 26% (interquartile range, 3%, 35%) improvement in oxygenation index at 30 ng x kg x min compared with placebo (p =.001). The response to prostacyclin was not the same in all children. We saw an improvement of > or = 20% in eight of 14 children (i.e., responders), and the number needed to treat was 1.8 (95% confidence interval, 1.2-3.2). No adverse effects were observed. CONCLUSIONS: Aerosolized prostacyclin improves oxygenation in children with acute lung injury. Future trials should investigate whether this treatment will positively affect outcome.
Authors: Brian M Fuller; Nicholas M Mohr; Lee Skrupky; Susan Fowler; Marin H Kollef; Christopher R Carpenter Journal: Chest Date: 2015-06 Impact factor: 9.410
Authors: Nathan Brunner; Vinicio A de Jesus Perez; Alice Richter; François Haddad; André Denault; Vanessa Rojas; Ke Yuan; Mark Orcholski; Xiaobo Liao Journal: Pulm Circ Date: 2014-03 Impact factor: 3.017
Authors: Anna T Brown; Jennifer V Gillespie; Franscesca Miquel-Verges; Kathryn Holmes; William Ravekes; Philip Spevak; Ken Brady; R Blaine Easley; W Christopher Golden; Leann McNamara; Michael A Veltri; Christoph U Lehmann; Kristen Nelson McMillan; Jamie M Schwartz; Lewis H Romer Journal: Pulm Circ Date: 2012 Jan-Mar Impact factor: 3.017
Authors: Nikolaos A Maniatis; Anastasia Kotanidou; John D Catravas; Stylianos E Orfanos Journal: Vascul Pharmacol Date: 2008-07-29 Impact factor: 5.773